{
    "organizations": [],
    "uuid": "e340e2ef5a81864cfc04f2c48cc293dfcd2bebfd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunicum-says-proceeds-according/brief-immunicum-says-proceeds-according-to-plan-with-ongoing-clinical-trials-for-ilixadencel-idUSFWN1RG03P",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunicum Says Proceeds According To Plan With Ongoing Clinical Trials For Ilixadencel",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Immunicum AB:\n* (PUBL) PROVIDES UPDATE ON ILIXADENCEL CLINICAL DEVELOPMENT PROGRAM\n* SAYS PROCEEDS ACCORDING TO PLAN WITH ONGOING CLINICAL TRIALS FOR ILIXADENCEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-03T14:12:00.000+03:00",
    "crawled": "2018-04-04T12:38:18.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "immunicum",
        "ab",
        "publ",
        "provides",
        "update",
        "ilixadencel",
        "clinical",
        "development",
        "program",
        "say",
        "proceeds",
        "according",
        "plan",
        "ongoing",
        "clinical",
        "trial",
        "ilixadencel",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}